The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

Three years after beginning construction in southwestern Wake County, the pharmaceutical company Amgen celebrated the ...

Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town.

Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a ...

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...